Valneva SE (NAS:VALN)
$ 4.3307 0.1342 (3.2%) Market Cap: 351.65 Mil Enterprise Value: 398.38 Mil PE Ratio: 0 PB Ratio: 1.60 GF Score: 69/100

Full Year 2019 Valneva SE Earnings Call Transcript

Feb 27, 2020 / 02:00PM GMT
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Valneva presents its full year 2019 results. (Operator Instructions) Also I must advise that the call is being recorded today, Thursday, the 27th of February 2020.

And without any further delay, I would now like to hand over the call to your first speaker today, Thomas Lingelbach, CEO of Valneva. Thank you. Please go ahead.

Thomas Lingelbach
Valneva SE - Chairman of the Management Board, President & CEO

Thank you so much. Good day, and very warm welcome to all of you to our call today where we're going to present our full year 2019 financial results as well as provide you with some business updates.

Well, I mean 2019 has been an exceptional year for Valneva. We have achieved our highest sales revenues ever from our 2 commercial travelers vaccines against Japanese encephalitis and cholera, and we have been able to make great progress on our 2 unique R&D programs.

If we look at Slide 4 of the presentation, we basically gained full control of R&D assets

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot